This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

Overview

This study will evaluate the efficacy and safety of deferasirox in patients with MDS, thalassemia and rare anemia patients with transfusion iron overload.

Full Title of Study: “1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2011

Interventions

  • Drug: Deferasirox

Arms, Groups and Cohorts

  • Experimental: Deferasirox

Clinical Trial Outcome Measures

Primary Measures

  • changes in ferritin level, compared to baseline, in patients with transfusion-induced iron overload treated with Exjade
    • Time Frame: Baseline assessment is followed by monthly assessments for up to 1 year

Secondary Measures

  • changes in clinical manifestations of iron overload by means of echocardiogram (ECHO), electrocardiogram (ECG), routine laboratory assessments and physical examination
    • Time Frame: Baseline assessment is followed by monthly assessments for up to 1 year.
  • changes in iron overload evidence on cardiac and liver magnetic resonance imaging (MRI) T2*, compared to baseline, in patients with transfusion-induced iron overload treated with Exjade
    • Time Frame: at baseline and 1 at year (at the end of study).
  • Number of participants with adverse events. Safety is evaluated through the continuous monitoring and recording of adverse events, as well as though routine laboratory assessments and physical examination.
    • Time Frame: From the start of study up to 1 year

Participating in This Clinical Trial

Inclusion Criteria

1. Age ≥ 2 years 2. Primary Diagnosis: Myelodysplastic Syndrome (presenting with low or intermediate-1 IPSS risk), thalassemia or rare anemias patients (anemia Diamond-Blackfan, Fanconi's anemia, Sideroblastic anemia, Red cell aplasia) 3. ECOG Performance Status ≤ 2 4. Transfusion overload confirmed with ferritin level >1000 µg/l. 5. No severe concomitant uncontrolled disease (uncontrolled diabetes mellitus, heart failure, renal failure). 6. Serum creatine level > ULN 7. No proteinuria 8. Liver enzymes level < 5 ULN. 9. No pregnancy or lactation 10. Signed informed consent by adults. In case inclusion of children under 18 years old, the informed consent should be signed by parents. Exclusion Criteria:

1. Age < 2 years 2. No iron overload (Ferritin level <1000 µg/l). 3. Primary iron overload (hereditary hemochromatosis) 4. Severe concomitant disease (uncontrolled diabetes mellitus, heart failure, renal failure) 5. Elevated serum creatinine > ULN or/and proteinuria 6. Liver enzymes level >5 ULN. 7. Pregnancy or lactation. Other protocol-defined inclusion/exclusion criteria may apply

Gender Eligibility: All

Minimum Age: 2 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Novartis Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Novartis Pharmaceuticals, Study Director, Novartis Pharmaceuticals

Citations Reporting on Results

Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010 Mar 25;115(12):2364-71. Epub 2009 Dec 8. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A; EPIC Study Investigators. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010 Apr;95(4):557-66. Epub 2009 Nov 30.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.